| A CFTR potentiator in patients with cystic fibrosis and the G551D mutation BW Ramsey, J Davies, NG McElvaney, E Tullis, SC Bell, P Dřevínek, ... New England Journal of Medicine 365 (18), 1663-1672, 2011 | 2399 | 2011 |
| Lumacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR CE Wainwright, JS Elborn, BW Ramsey, G Marigowda, X Huang, M Cipolli, ... New England Journal of Medicine 373 (3), 220-231, 2015 | 1508 | 2015 |
| Effect of high-dose ibuprofen in patients with cystic fibrosis MW Konstan, PJ Byard, CL Hoppel, PB Davis New England Journal of Medicine 332 (13), 848-854, 1995 | 945 | 1995 |
| Inflammatory cytokines in cystic fibrosis lungs. TL Bonfield, JR Panuska, MW Konstan, KA Hilliard, JB Hilliard, H Ghnaim, ... American journal of respiratory and critical care medicine 152 (6), 2111-2118, 1995 | 920 | 1995 |
| Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation FJ Accurso, SM Rowe, JP Clancy, MP Boyle, JM Dunitz, PR Durie, ... New England Journal of Medicine 363 (21), 1991-2003, 2010 | 913 | 2010 |
| Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation JP Clancy, SM Rowe, FJ Accurso, ML Aitken, RS Amin, MA Ashlock, ... Thorax 67 (1), 12-18, 2012 | 650 | 2012 |
| Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. MW Konstan, KA Hilliard, TM Norvell, M Berger American journal of respiratory and critical care medicine 150 (2), 448-454, 1994 | 645 | 1994 |
| Genetic modifiers of lung disease in cystic fibrosis ML Drumm, MW Konstan, MD Schluchter, A Handler, R Pace, F Zou, ... New England Journal of Medicine 353 (14), 1443-1453, 2005 | 611 | 2005 |
| Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy AM Cantin, D Hartl, MW Konstan, JF Chmiel Journal of Cystic Fibrosis 14 (4), 419-430, 2015 | 532 | 2015 |
| A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised … MP Boyle, SC Bell, MW Konstan, SA McColley, SM Rowe, E Rietschel, ... The lancet Respiratory medicine 2 (7), 527-538, 2014 | 521 | 2014 |
| Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. TL Bonfield, MW Konstan, P Burfeind, JR Panuska, JB Hilliard, M Berger American journal of respiratory cell and molecular biology 13 (3), 257-261, 1995 | 460 | 1995 |
| Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis MW Konstan, WJ Morgan, SM Butler, DJ Pasta, ML Craib, SJ Silva, ... The Journal of pediatrics 151 (2), 134-139. e1, 2007 | 454 | 2007 |
| Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis MW Konstan, SM Butler, MEB Wohl, M Stoddard, R Matousek, ... The Journal of pediatrics 142 (6), 624-630, 2003 | 448 | 2003 |
| Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial MW Konstan, PA Flume, M Kappler, R Chiron, M Higgins, F Brockhaus, ... Journal of Cystic Fibrosis 10 (1), 54-61, 2011 | 421 | 2011 |
| Current understanding of the inflammatory process in cystic fibrosis: onset and etiology MW Konstan, M Berger Pediatric pulmonology 24 (2), 137-142, 1997 | 407 | 1997 |
| Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis EC Dasenbrook, W Checkley, CA Merlo, MW Konstan, N Lechtzin, ... Jama 303 (23), 2386-2392, 2010 | 390 | 2010 |
| Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis RL Gibson, J Emerson, S McNamara, JL Burns, M Rosenfeld, A Yunker, ... American journal of respiratory and critical care medicine 167 (6), 841-849, 2003 | 386 | 2003 |
| Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial E Kerem, MW Konstan, K De Boeck, FJ Accurso, I Sermet-Gaudelus, ... The Lancet Respiratory Medicine 2 (7), 539-547, 2014 | 376 | 2014 |
| A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities JM Quan, HAWM Tiddens, JP Sy, SG McKenzie, MD Montgomery, ... The Journal of pediatrics 139 (6), 813-820, 2001 | 365 | 2001 |
| Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator … MW Konstan, PB Davis, JS Wagener, KA Hilliard, RC Stern, LJH Milgram, ... Human gene therapy 15 (12), 1255-1269, 2004 | 360 | 2004 |
